MOLNMolecular Partners AG

MOLN Stock Price, Valuation & Chart | Molecular Partners AG

Compare

$4.070-0.21 (-5.02%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MOLN intrinsic value MOLN calculated fair value vs price

Overview Financials Dividends Ratios

MOLN Historical price chart

MOLN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization152.67M

PE Ratio-2.39

EPS-1.71

Trading Volume276

Today's High/Low4.22/4.07

Dividend Yield0.00

52 Week High/Low5.36/3.53

Shares Outstanding37.51M

MOLN Financial Statement

MOLN Analyst ratings

MOLN Analysis & performance metrics

MOLN Company profile

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its…

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and…

MOLN Management team

Name

Position

Seth D. Lewis

Senior Vice President of Investor Relations, Communications & Strategy

Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

Michael Pitzner

General Counsel, Compliance Officer, Senior Vice President Legal & Business Development

Pamela A. Trail Ph.D.

Strategic Consultant

Robert Hendriks

Senior Vice President of Finance

Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Patrick Amstutz Ph.D.CEO

Co-Founder, Chief Executive Officer, Member of Management Board & Director

Michael Tobias Stumpp Ph.D.

Co-Founder, Executive Vice President of Projects & Member of Management Board

Name

Position

Seth D. Lewis

Senior Vice President of Investor Relations, Communications & Strategy

Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

Michael Pitzner

General Counsel, Compliance Officer, Senior Vice President Legal & Business Development

Pamela A. Trail Ph.D.

Strategic Consultant

Robert Hendriks

Senior Vice President of Finance

Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Patrick Amstutz Ph.D.CEO

Co-Founder, Chief Executive Officer, Member of Management Board & Director

Michael Tobias Stumpp Ph.D.

Co-Founder, Executive Vice President of Projects & Member of Management Board

Management Team

Seth D. Lewis

Senior Vice President of Investor Relations, Communications & Strategy

Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

Michael Pitzner

General Counsel, Compliance Officer, Senior Vice President Legal & Business Development

Pamela A. Trail Ph.D.

Strategic Consultant

Robert Hendriks

Senior Vice President of Finance

Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Patrick Amstutz Ph.D.CEO

Co-Founder, Chief Executive Officer, Member of Management Board & Director

Michael Tobias Stumpp Ph.D.

Co-Founder, Executive Vice President of Projects & Member of Management Board

Management

Seth D. Lewis

Senior Vice President of Investor Relations, Communications & Strategy

Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

Michael Pitzner

General Counsel, Compliance Officer, Senior Vice President Legal & Business Development

Pamela A. Trail Ph.D.

Strategic Consultant

Robert Hendriks

Senior Vice President of Finance

Daniel Steiner Ph.D.

Senior Vice President of Research & Technology

Patrick Amstutz Ph.D.CEO

Co-Founder, Chief Executive Officer, Member of Management Board & Director

Michael Tobias Stumpp Ph.D.

Co-Founder, Executive Vice President of Projects & Member of Management Board

Total 8 executives

MOLN Frequently asked questions

What is Molecular Partners AG (MOLN) Stock Price?

Current stock price of Molecular Partners AG (MOLN) stock is $4.070. The stock price is -5.02% lower in the session. The intraday range can be seen from this page. Volume of Molecular Partners AG (MOLN) stock is 276.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Molecular Partners AG (MOLN) stock price going up or down today?

The stock price of Molecular Partners AG (MOLN) can change with earnings, company news, and overall market sentiment. Molecular Partners AG operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Molecular Partners AG stock expensive at its current price?

Whether Molecular Partners AG looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MOLN on this page is -2.39. EPS on this page is -1.71. Compare those figures with peers and growth expectations before deciding if the current Molecular Partners AG price is justified.

How has the stock price of Molecular Partners AG (MOLN) performed historically?

Historical performance for Molecular Partners AG (MOLN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MOLN reacted to past earnings and market events.

Should I buy Molecular Partners AG (MOLN) stock, at this price?

Buying Molecular Partners AG (MOLN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.